Try our beta test site
41 studies found for:    Gilead | hepatitis c | Phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Peg-IFN
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2012
Primary Completion: October 2014
2 Not yet recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2017
Primary Completion: July 2017
3 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: April 2016
Primary Completion: January 2018
4 Active, not recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: April 4, 2016
Primary Completion: July 2017
5 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2016
Primary Completion: January 2018
6 Completed Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: November 2015
Primary Completion: October 2016
7 Active, not recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
Condition: Hepatitis C Virus Infection
Intervention: Drug: LDV/SOF
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: January 2017
8 Completed Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: February 2015
Primary Completion: March 2016
9 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 7, 2015
Primary Completion: November 11, 2016
10 Completed Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2015
Primary Completion: April 2016
11 Completed Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Condition: Hepatitis C Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2015
Primary Completion: March 2016
12 Active, not recruiting Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: April 12, 2016
Primary Completion: February 14, 2017
13 Completed Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: October 2016
14 Completed Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: October 2016
15 Completed
Has Results
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2012
Primary Completion: November 2013
16 Completed
Has Results
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C Virus
Interventions: Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2013
Primary Completion: May 2014
17 Completed
Has Results
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: January 2013
Primary Completion: April 2014
18 Active, not recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/VOX;   Drug: Placebo
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: November 2015
Primary Completion: October 2016
19 Active, not recruiting Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2016
Primary Completion: August 2017
20 Completed
Has Results
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Peg-IFN
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 2013
Primary Completion: January 2015

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.